Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Research Institute of the Southeast
mi
from
West Palm Beach, FL
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Research Institute of the Southeast
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Visions Clincal Research
mi
from
West Palm Beach, FL
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Visions Clincal Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
MedaPhase, Inc.
mi
from
Newnan, GA
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
MedaPhase, Inc.
mi
from
Newnan, GA
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Research Institute of Deaconess Clinic
mi
from
Evansville, IN
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Research Institute of Deaconess Clinic
mi
from
Evansville, IN
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
DermAssociates, PC
mi
from
Rockville, MD
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
DermAssociates, PC
mi
from
Rockville, MD
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Clarkston Skin Research
mi
from
Clarkston, MI
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Clarkston Skin Research
mi
from
Clarkston, MI
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Clinical Studies Group, LLC
mi
from
Henderson, NV
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Clinical Studies Group, LLC
mi
from
Henderson, NV
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
The Dermatology Group, P.C.
mi
from
Verona, NJ
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
The Dermatology Group, P.C.
mi
from
Verona, NJ
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Skin Search of Rochester, Inc
mi
from
Rochester, NY
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Suzanne Bruce and Associates The Center for Skin Research
mi
from
Katy, TX
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Suzanne Bruce and Associates The Center for Skin Research
mi
from
Katy, TX
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Surrey,
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Surrey,
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
The GW Medical Faculty Associates
mi
from
Washington,
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
The GW Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Scottsdale
mi
from
Scottsdale, AZ
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Durham
mi
from
Durham, NC
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Durham
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Oklahoma
mi
from
Oklahoma City, OK
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Investigator Site - Nashville
mi
from
Nashville, TN
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Investigator Site - Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Investigator Site - Salt Lake City
mi
from
Salt Lake City, UT
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Investigator Site - Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
St. Josephs Heritage Healthcare
mi
from
Santa Rosa, CA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
St. Josephs Heritage Healthcare
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sarasota Memorial Health Care System
mi
from
Sarasota, FL
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sarasota Memorial Health Care System
mi
from
Sarasota, FL
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
MUMC - Curtis and Elizabeth Anderson Cancer Institute
mi
from
Savannah, GA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
MUMC - Curtis and Elizabeth Anderson Cancer Institute
mi
from
Savannah, GA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
St. Dominic-Jackson Memorial Hospital
mi
from
Jackson, MS
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
St. Dominic-Jackson Memorial Hospital
mi
from
Jackson, MS
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rapid City Regional Cancer Care
mi
from
Rapid City, SD
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rapid City Regional Cancer Care
mi
from
Rapid City, SD
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
UCLA
mi
from
Los Angeles, CA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Cancer Institute
mi
from
Orlando, FL
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
mi
from
Dallas, TX
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Providence St. Joseph Medical Center - Gynecology
mi
from
Burbank, CA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Providence St. Joseph Medical Center - Gynecology
mi
from
Burbank, CA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Cancer Institute-UC Health Barrett Center
mi
from
Cincinnati, OH
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Cancer Institute-UC Health Barrett Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Northside Hospital [University Gynecologic Oncology]
mi
from
Atlanta, GA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Northside Hospital [University Gynecologic Oncology]
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Care [Mary Bird Cancer Center at Tammany Parish Hospital]
mi
from
Covington, LA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Care [Mary Bird Cancer Center at Tammany Parish Hospital]
mi
from
Covington, LA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
UT Galveston; University of Texas Medical Branch (UTMB)
mi
from
Galveston, TX
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
UT Galveston; University of Texas Medical Branch (UTMB)
mi
from
Galveston, TX
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of California - Irvine Healthcare
mi
from
Irvine, CA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of California - Irvine Healthcare
mi
from
Irvine, CA
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Colorado School of Medicine, Division of Gynecologic Oncology
mi
from
Aurora, CO
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Colorado School of Medicine, Division of Gynecologic Oncology
mi
from
Aurora, CO
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials